摘要
中美贸易谈判及第一轮协议的签署,对中国药品专利制度影响深远。通过文本梳理和规范分析,并联系中美关系的时政背景,可以对药品专利制度可能受到的冲击进行预判,同时为下一轮中美谈判和《中华人民共和国专利法》第四次修改改相关事项建言。中国应当正确理解和运用专利立法的利益平衡原理,在落实中美谈判结果的过程中保持开放心态,高水准体系化地推进药品专利链接制度的改革。同时坚持最大限度维护国家利益的基本原则,在药品专利申请补充实验数据规则方面进行最低限度落实。药品专利强制许可问题将成为中美下一轮贸易谈判的重要议题,中国应主动将药品专利保护与人类基本健康权益的利益平衡话题列入谈判目录并做好论证准备,同时考虑国际条约的弹性规定,完善国内相关立法。
The China-US trade negotiations and the signing of the first round of agreements will have a certain impact on China’s pharmaceutical patent system.Through text sorting and normative analysis,and given the current political background of China-US relations,it is possible to prejudge the coming impact of the pharmaceutical patent system,and at the same time,make suggestions for related matters in the next round of China-US negotiations.China should correctly understand and apply the principle of interest balance in patent legislation,maintain an open mind in the process of implementing the results of China-US negotiations,and actively carry out reform of the generic patent linkage system.At the same time,China should adhere to the basic principle of maximizing the national lawful interests and defend the final line of allowing supplemental data in pharmaceutical patent applications.The issue of compulsory licensing of pharmaceutical patents should become an important topic in the next round of China-US negotiations.China should actively include the topic of the balance of interests between pharmaceutical patent protection and human basic health rights in the negotiations.At the same time,the relevant provisions of the domestic law regarding the compulsory licensing system for pharmaceutical patents should further its improvement in accordance with the flexible provisions of international treaties.
出处
《私法》
2021年第2期88-106,共19页
Private Law Review
作者简介
吴柯苇(1993一),北京大学法学院2019级博士研究生,主要研究方向:知识产权法、科技法。
